A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Exclusion Criteria

• •A History of severe adverse reaction or allergy to any medical product.
• •Clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal, renal, cardiovascular disease, eye disorder or history of psychiatric/psychotic disorder.
• •A history of tuberculosis.
• •Have a positive HBsAg, HBcAb, HCVAb or HIV-1 and HIV-2 test.
• •Previously having received MT-1303, fingolimod, or any other sphingosine-1-phosphate receptor modulators.
• •Clinical relevant abnormal medical history, or physical findings or laboratory values.
• •Clinically significant 12-lead ECG abnormalities.
• •Clinical relevant abnormal findings in echocardiograph.